 Lexaria Bioscience Corp. NASDAQ:LEXX shares are trading higher after the company announced its DehydraTECH significantly enhances delivery of colchicine in study VIRAL-A20-3. This study demonstrated that DehydraTECHTM enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, said in the companys press release. 